Loading...
•
Sep 30
STERIS Q2 2026 Earnings Report
STERIS reported higher revenue and profit in Q2 2026, with strong performance across all major business segments.
Key Takeaways
STERIS delivered strong Q2 2026 results with revenue rising to $1.46 billion and net income reaching $191.9 million. Growth was seen across Healthcare, AST, and Life Sciences segments, with notable increases in service and consumables revenue.
Total revenue rose to $1.46 billion in Q2 2026 from $1.33 billion in Q2 2025
Diluted EPS increased to $1.94, up from $1.51 in the prior-year quarter
Free cash flow for the quarter reached approximately $347.7 million (half-year: $527.7 million)
All segments — Healthcare, AST, and Life Sciences — experienced double-digit organic growth
STERIS
STERIS
STERIS Revenue by Segment
STERIS Revenue by Geographic Location
Revenue by Segment
Healthcare Revenue
CapyFin.comAST Revenue
CapyFin.comLife Sciences Revenue
CapyFin.comRevenue by Geographic Location
Ireland Revenue
CapyFin.comUnited States Revenue
CapyFin.comInternational Revenue
CapyFin.com Forward Guidance
STERIS reaffirmed its FY 2026 outlook with strong expectations for adjusted EPS and free cash flow, supported by momentum across core business units.
Positive Outlook
- Adjusted EPS guidance raised to $10.15–$10.30
- FY26 free cash flow projected at $850 million
- Healthcare backlog increased to $427.5 million
- Service and consumable revenue showing consistent growth
- Strong operating leverage across AST and Life Sciences
Challenges Ahead
- Capital equipment revenue growth modest in Healthcare and declined in AST
- Corporate expenses continue to weigh on consolidated margins
- Currency headwinds impacted constant currency growth
- Restructuring charges and integration costs persist
- Lower contribution from discontinued operations compared to prior year
Revenue & Expenses
Visualization of income flow from segment revenue to net income